Diffuse large B-cell lymphoma is an aggressive tumor of the lymphatic system. These tumors are known to be both molecularly and biologically heterogenous. They respond differently to treatments, which is why they are classified into subtypes and subgroups. Metabolic signatures, however, are not included in the current classification. Past attempts were met with caution, as studies of extracted tissue can suffer from bias due to the artificial microenvironment. We propose an advanced MRI technique that allows examination of biochemical changes in tumors without taking tissue samples. It provides the unique opportunity to non-invasively collect metabolic fingerprints of tumor manifestations in patients with the ultimate goal of identifying metabolic markers for therapy stratification.
Here you can find further information.